An in silico study on Antidiabetic activity DPP-IV inhibitorsand bioactive compounds Boesenbergia pandurata Roxb

Nidianti, Ersalina and Rukman, Nia Kurniaty (2020) An in silico study on Antidiabetic activity DPP-IV inhibitorsand bioactive compounds Boesenbergia pandurata Roxb. Surabaya International Health Conference, 1 (1). pp. 122-127.

[img] PDF
An in silico study on Antidiabetic activity DPP-IV inhibitorsand bioactive compounds Boesenbergia pandurata Roxb.pdf

Download (552kB)
[img] PDF
peer review.pdf

Download (91kB)
[img] PDF
turnitin.pdf

Download (1MB)
Official URL: https://conferences.unusa.ac.id/index.php/SIHC19/a...

Abstract

Diabetes type 2 is a disease caused by a metabolic disorder. One of treatment of type 2 diabetes mellitus is focused on incretin hormone. Glucagon like peptide – 1 (GLP-1) is a insulintropic agent and plays a role in regulation of blood glucose. GLP-1 interacts with GLP-1R so the blood sugar level increases. DPP – IV is inhibitor are important biological target related for the treatmen of type 2 diabetes mellitus. DPP-IV inhibitor from drug synthetic have some side effect therefore develop natural DPP-IV inhibitor by in silico approaches. This research is study molecular interaction between DPP – IV inhibitor drug synthetic on the market was sitagliptin, vildagliptin, saxagliptin, anagliptin and alogliptin with compare bioactive ligan from Boesenbergia pandurata Roxb such as alipinetin, pinocembrin, pinostrobin, cardamonin, panduratin. The metodology used in the research is molecular docking using docking software. The results showed that DPP – IV inhibitor with vildagliptin had the best binding energy 15.49 Kcal/mol and torsional energy 19.69. Based on the analysis of docking in silico DPP-IV inhibitors with active compound Boesenbergia pandurata Roxb has binding energy 2.39 Kcal/mol and torsional energy 5.5 and can be used as an antidiabetic drug candidate.

Item Type: Article
Uncontrolled Keywords: In Silico, Dipeptidyl peptidase IV, Beosenbergia pandurata Roxb, GLP-1, Diabetes mellitus, molecular docking.
Subjects: R Medicine > RS Pharmacy and materia medica
Divisions: Faculty of Health > Program Study of Health Analyst
Depositing User: Mr. . Aji
Date Deposited: 22 Aug 2020 06:05
Last Modified: 22 Aug 2020 06:05
URI: http://repository.unusa.ac.id/id/eprint/6230

Actions (login required)

View Item View Item